Rhythm Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-02-01
- Employees
- 226
- Market Cap
- -
- Website
- http://www.rhythmtx.com
- Introduction
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Open-Label Study of Setmelanotide in Hypothalamic Obesity
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04725240
- Locations
- 🇺🇸
Children's Minnesota, Saint Paul, Minnesota, United States
🇺🇸Seattle Children's Research Institute, Seattle, Washington, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04348175
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT03746522
- Locations
- 🇺🇸
Wr-McCr, Llc, San Diego, California, United States
🇺🇸Columbia University Center, New York, New York, United States
🇺🇸M3 Wake Research, Raleigh, North Carolina, United States
Long Term Extension Trial of Setmelanotide
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT03651765
- Locations
- 🇺🇸
Obesity Institute, Geisinger Clinic, Danville, Pennsylvania, United States
🇺🇸Wake Research, Raleigh, North Carolina, United States
🇺🇸Wake Research TN, Chattanooga, Tennessee, United States
An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes
- Conditions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03621007
- Locations
- 🇹🇷
Ege University School of Medicine of Pediatric Endocrinology, Bornova, Turkey
🇹🇷Pediatric Endocrinology and Diabetes Marmara University Hospital, Istanbul, Turkey
🇹🇷Dokuz Eylul Universitesi Tip Fakultesi, Balçova, Turkey
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry
- Conditions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 303
- Registration Number
- NCT03479437
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇨🇦University of Alberta, Edmonton, Canada
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
- Conditions
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03287960
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇩🇪University of Ulm, Ulm, Germany
🇨🇦Markham Stouffville Hospital, Markham, Ontario, Canada
Setmelanotide in a Single Patient With Partial Lipodystrophy
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT03262610
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT03013543
- Locations
- 🇺🇸
AXIS South Florida Clinical Trials, Hialeah, Florida, United States
🇺🇸Synexus Clinical Research US, Inc. - Akron, Akron, Ohio, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
- Conditions
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02896192
- Locations
- 🇩🇪
Charité Campus Virchow-Klinikum / Institute for Experimental Pediatric Endocrinology, Berlin, Germany
🇬🇧University of Cambridge Metabolic Research Laboratories, Cambridge, United Kingdom
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States